blepharitis
BLEPHARITIS
Blepharitis is an inflammation process affecting the eyelid margins, eyelash follicles or openings of the anteriorly-placed accessory lacrimal glands and the posteriorly-placed Meibomian glands that causes ocular irritation and redness acutely but usually chronically.
It may have periods of exacerbations and remissions.
It usually occurs in middle-aged adults but can also start in childhood.
Can affect vision by disrupting the surface of the cornea and the bulbar conjunctiva; may influence tear film composition.
Drug Information

Indication: Purulent bacterial & trachomatous conjunctivitis caused by Chlamydia trachomatis in adults & childn fr...

Indication: Ophth Conjunctivitis, corneal injuries, superficial punctuate keratitis, vernal keratoconjunctivitis. Adjunct ...

Indication: Ocular infections involving conjunctiva &/or cornea due to susceptible organisms.

Indication: Bacterial conjunctivitis.

Indication: Local treatment for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated ...

Indication: Bacterial eye infections caused by susceptible organisms in conjunctivitis, blepharitis, sty, keratitis, dacry...

Indication: Ocular infections involving conjunctiva &/or cornea caused by chlorampenicol-susceptible organisms

Indication: Fungal blepharitis, conjunctivitis & keratitis caused by susceptible organisms.

Neo-Deca
dexamethasone sodium phosphate + neomycin sulfate

Indication: Acute steroid-responsive inflammatory & allergic conditions w/ accompanying bacterial infections.

1  /  4
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.